Nervgen Pharma Corp (NGENF)

$2.46 -0.03 (-1.17%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 62,000
Avg Vol 231,186
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 15%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study....

Industry: Biotechnology
Sector: Healthcare
Phone: 778-731-1711
Address:
112-970 Burrard Street, Unit 1290, Vancouver, Canada
Lunasicc42
Lunasicc42 Aug. 1 at 3:14 PM
$NGENF why is the dates of nervgens Meetings with the FDA not scheduled and public information? I mean, someone has to know.
1 · Reply
aladdinscarpet
aladdinscarpet Aug. 1 at 12:38 AM
$NGENF perhaps worst PR of a major medical breakthrough in a very long time. Difficult to reconcile TLR with subsequent events. Detailed data release might make more news, but not holding my breath. Does anybody even care?
3 · Reply
DM50418
DM50418 Jul. 31 at 8:45 PM
$NGENF When Fast Track was granted a long time ago, the company was never very clear about their FDA interactions and also how/if they set up the Phase 1b/2a trial with input or agreement from the FDA staff on our primary and secondary endpoints. I would love to have been there or be able to review those meeting notes now. Nervgen: Please push for a Priority Review. In order to be granted Priority Review, with our current results and no other approved treatments available, the question is if SCI meets the definition of life-threatening or severely-debilitating in accordance with 21CFR312.82. This is where I would argue yes. The WHO says that SCI is associated with a risk of developing secondary conditions that can be debilitating and even life-threatening—e.g. deep vein thrombosis, urinary tract infections, muscle spasms, osteoporosis, pressure ulcers, chronic pain, and respiratory complications.
4 · Reply
DM50418
DM50418 Jul. 31 at 6:01 PM
$NGENF I expect the full data release within the next few weeks and a PR at the same time that the FDA meeting has been scheduled. Look at other companies where FDA expedited approval has been based on 20 patient studies. We completed a placebo-controlled trial with an extremely safe drug that had a clear win with our surrogate endpoint (and positive trend in one important function) where there is currently no FDA-approved drug.
2 · Reply
Zeppieddodaw
Zeppieddodaw Jul. 31 at 5:16 PM
$NGENF Will need to raise cash some time soon. I expect stock issuance will dilute shares some. Still long term investor and hopeful.
1 · Reply
ReggieTrades
ReggieTrades Jul. 30 at 1:13 AM
$NGENF The FDA just got better.
2 · Reply
timfris
timfris Jul. 29 at 9:24 PM
$NGENF did this company just give up? CEO and CMO gone. This was pretty groundbreaking news, and only a few hundred investors and patients know about it.
2 · Reply
ReggieTrades
ReggieTrades Jul. 29 at 4:46 AM
$NGENF A question for the more experienced investors here: If their next catalyst doesn't boost the share price high enough to up-list, is their only option a reverse split? I really don't see the getting AA from this ridiculous FDA. The sub acute readout is the only catalyst that I know of.
2 · Reply
libertyjc
libertyjc Jul. 29 at 2:00 AM
$NGENF buying all day down here especially after the derisking data
0 · Reply
1_sitting_bull
1_sitting_bull Jul. 26 at 10:54 AM
$NGENF
1 · Reply
Latest News on NGENF
No data available.
Lunasicc42
Lunasicc42 Aug. 1 at 3:14 PM
$NGENF why is the dates of nervgens Meetings with the FDA not scheduled and public information? I mean, someone has to know.
1 · Reply
aladdinscarpet
aladdinscarpet Aug. 1 at 12:38 AM
$NGENF perhaps worst PR of a major medical breakthrough in a very long time. Difficult to reconcile TLR with subsequent events. Detailed data release might make more news, but not holding my breath. Does anybody even care?
3 · Reply
DM50418
DM50418 Jul. 31 at 8:45 PM
$NGENF When Fast Track was granted a long time ago, the company was never very clear about their FDA interactions and also how/if they set up the Phase 1b/2a trial with input or agreement from the FDA staff on our primary and secondary endpoints. I would love to have been there or be able to review those meeting notes now. Nervgen: Please push for a Priority Review. In order to be granted Priority Review, with our current results and no other approved treatments available, the question is if SCI meets the definition of life-threatening or severely-debilitating in accordance with 21CFR312.82. This is where I would argue yes. The WHO says that SCI is associated with a risk of developing secondary conditions that can be debilitating and even life-threatening—e.g. deep vein thrombosis, urinary tract infections, muscle spasms, osteoporosis, pressure ulcers, chronic pain, and respiratory complications.
4 · Reply
DM50418
DM50418 Jul. 31 at 6:01 PM
$NGENF I expect the full data release within the next few weeks and a PR at the same time that the FDA meeting has been scheduled. Look at other companies where FDA expedited approval has been based on 20 patient studies. We completed a placebo-controlled trial with an extremely safe drug that had a clear win with our surrogate endpoint (and positive trend in one important function) where there is currently no FDA-approved drug.
2 · Reply
Zeppieddodaw
Zeppieddodaw Jul. 31 at 5:16 PM
$NGENF Will need to raise cash some time soon. I expect stock issuance will dilute shares some. Still long term investor and hopeful.
1 · Reply
ReggieTrades
ReggieTrades Jul. 30 at 1:13 AM
$NGENF The FDA just got better.
2 · Reply
timfris
timfris Jul. 29 at 9:24 PM
$NGENF did this company just give up? CEO and CMO gone. This was pretty groundbreaking news, and only a few hundred investors and patients know about it.
2 · Reply
ReggieTrades
ReggieTrades Jul. 29 at 4:46 AM
$NGENF A question for the more experienced investors here: If their next catalyst doesn't boost the share price high enough to up-list, is their only option a reverse split? I really don't see the getting AA from this ridiculous FDA. The sub acute readout is the only catalyst that I know of.
2 · Reply
libertyjc
libertyjc Jul. 29 at 2:00 AM
$NGENF buying all day down here especially after the derisking data
0 · Reply
1_sitting_bull
1_sitting_bull Jul. 26 at 10:54 AM
$NGENF
1 · Reply
PETESHICK
PETESHICK Jul. 25 at 11:09 PM
$NGENF https://youtu.be/CVWytzFFV2Q?si=xoTxfgk_T0BC1xJ9
2 · Reply
Rexpower
Rexpower Jul. 25 at 10:47 PM
$NGENF Stock has been stagnant for a bit but NVG-291 still has a decent chance of getting Accelerated Approval. Based on the FDA website the drug must be used to treat a serious condition, and fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint does not have to be functional improvements. Per FDA a surrogate endpoint could be laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. I don't see why the increase in EMP wouldnt be considered a surrogate endpoint. Serious condition- check Umet medical need- check Surrogate endpoint- certainly seems like it.
3 · Reply
DataJim
DataJim Jul. 24 at 6:46 PM
$NGENF Our brilliant scientist is dead. Our CMO and our CEO both resigned after Data release. I’m moving some of my investment to $TLSA . Their brilliant scientist is still alive and they’re going after MS first which is closer to my heart as an MS patient. I’m still invested here somewhere and definitely still rooting for this company and its drugs.
7 · Reply
rwelsh633
rwelsh633 Jul. 24 at 5:05 PM
$NGENF I am anticipating full set of data to be released anytime now, was curious when that will be so I called NervGen. Discussed their current search for CEO & CMO, and he made it sound like they are not hinging meeting with the FDA until they get a new CEO or CMO they feel they have the right people in place but are still being very cautious as they know they have a product that works so the risk is off and they need to have a good presentation for FDA.
4 · Reply
Mark_Venture
Mark_Venture Jul. 24 at 3:23 AM
$NGENF https://www.barrons.com/market-data/stocks/ngenf/research-ratings
0 · Reply
rwelsh633
rwelsh633 Jul. 23 at 4:21 PM
$NGENF Someone finally gets it! Price target $14.60. IMO It will be higher than that in the 1-2 years. https://www.cantechletter.com/2025/07/nervgen-pharma-is-a-buy-research-capital-says/
3 · Reply
libertyjc
libertyjc Jul. 22 at 4:08 AM
$NGENF The board is working hard to create value here…staying long and strong
0 · Reply
Smithcommajon
Smithcommajon Jul. 21 at 4:33 PM
$NGENF Im so confused by this company. I still dont understand why the stock price hasnt moved. Im confident the drug will be approved but im unsure if i should dump more cash into the stock. The management has been very poor. The CEO leaving is bad and they have been so quite. Im on the fence.
4 · Reply
ada3
ada3 Jul. 21 at 2:38 PM
$HGRAF Jay Taylor "This week as it became clear to me that investors were finally waking up to the massive potential of Hydrograph Clean Power, I had to find a way to increase my shares. With no dry powder, I had to part ways with a portion of Cerro de Pasco, Lahontan, and Sprott Silver Miners. And I had to sell NervGen ($NGENF)as well, to take my portfolio allocation close to 40%." "We make the best Graphene in the World!" Watch Youtube https://youtu.be/oLxQI8RCXjc
3 · Reply
philmitchell
philmitchell Jul. 21 at 2:26 AM
$NGENF From Laugh_alotl_axolotl a trial participant on Reddit: “Today at my church I took communion independently, although the cup is very small. Last year, I was one of 10 people with a chronic spinal cord injury to be dosed with NVG-291 in the NervGen clinical trial at the Shirley Ryan Ability Lab. I was hurt almost 10 years ago. It made me happy to independently participate in this rite of my faith.” https://www.reddit.com/r/NervGen_NerveRepair/s/JBmkiWeAhn
0 · Reply
DM50418
DM50418 Jul. 19 at 8:47 PM
$NGENF He might be a little biased (one of the four inventors on the primary patent), but this is the kind of post that should have been making news over a month ago. https://www.linkedin.com/posts/brad-lang-43305584_its-been-over-a-week-since-nervgen-pharma-activity-7338990294064865282-cV8N It's been over a week since NervGen Pharma released their clinical trial results in chronic cervical spinal cord injury, and I keep coming back to one key takeaway and this figure: NVG-291 may be the… | Brad Lang
0 · Reply
ReggieTrades
ReggieTrades Jul. 19 at 6:50 PM
$NGENF I really don't see the justification for Kelly's exit. They do have to be careful not to look like they're pumping this thing too much. The results showed that it's still far from known what the optimal dosing regimen will look like. It could be astronomical in expense to run all the trials to figure it out. And that's just for spinal cord injury. I wouldn't rule out them taking it to market on an experimental basis like stem cell treatments. The number of clinics treating pain, joints, and other problems with non FDA approved stem cell treatments is quite large. Anyhow... I don't think they really do know which direction they're headed. But the FDA approved path is going to be long and expensive.
3 · Reply